Nkem Ogbechie

Nkem Ogbechie is a board member at California Lutheran University. Nkem previously worked as the global product general manager at Amgen from November 2019 to July 2021. During their time at Amgen, they were responsible for leading global product strategy development for both Prolia (denosumab) and EVENITY (romosozumab), serving millions of patients across 85 countries, and $3.1 billion in total revenues in 2020.

Ogbechie set an integrated product strategy that navigated near-term competitive pressures, considered long-term market factors, and reflected global, regional, and country perspectives. Nkem also defined franchise vision, articulated strategic choices, set team goals, aligned activities, and led two cross-functional product teams accountable for product lifecycle. In addition, they supported successful launches of EVENITY in Europe, the Middle East, and Latin America and Prolia in China; managed partnerships with Daiichi-Sankyo and UCB; fostered collaboration with global and national advocacy and policy groups. Lastly, they developed strategic trade-offs and articulated brand plan to defend Amgen’s global value and risk profile, including government affairs, legal, intellectual property, compliance, and corporate affairs.

Nkem Ogbechie has a BA in Human Biology from Stanford University, an MBA in Finance and Healthcare Management from Rice University's Jesse H. Jones Graduate School of Management, and a Harvard Extension School Graduate Certificate in Biotechnology Management - Genetics from Harvard University.